Wave Life Sciences: director Ken Takanashi received 74,700 shares

What happened

• The filing shows Ken Takanashi, a director, was granted 10,700 restricted stock units (RSUs) and a 64,000-share option on Oct 5, 2026. Both acquisitions are reported at a price of $0.

Key details

• Transaction date: Oct 5, 2026; both items reported as acquisition code A; reported price $0.
• Post-transaction holdings reported in the filing include 10,700 RSUs and a 64,000-share option, and an aggregate of 9,606,408 shares of common stock held by SNBL USA, Ltd. (6,107,593) and Shin Nippon Biomedical Laboratories, Ltd. (3,498,815) (see footnote 3).
• Vesting: the RSU and the option vest 100% on the earlier of the company's 2027 annual meeting of stockholders or Oct 5, 2027 (footnotes 1 and 2).
• Footnote 4 states Mr. Takanashi is a director of SNBL USA and SNBL and may be deemed to beneficially own the reported securities held by those entities, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
• Filing date: Oct 7, 2026; report covers transactions on Oct 5, 2026.

Why it may matter

• These were grant awards, not market purchases or sales.
• The 64,000 item is an option award (a derivative), the 10,700 item is an RSU award; both vest as described above.
• The filing shows large share totals held by SNBL USA and SNBL but the filing also includes a disclaimer about beneficial ownership.
• This filing does not show why the insider traded or why the company acted.